- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2014 (2014), Article ID 310981, 11 pages
Enhanced Amelioration of High-Fat Diet-Induced Fatty Liver by Docosahexaenoic Acid and Lysine Supplementations
1Department of Animal Science and Technology, National Taiwan University, No. 50, Lane 155, Section 3, Keelung Road, Da'an District, Taipei City 106, Taiwan
2Institute of Biotechnology, National Taiwan University, No. 81, Changxing Street, Da'an District, Taipei City 106, Taiwan
Received 14 November 2013; Revised 15 April 2014; Accepted 29 April 2014; Published 25 May 2014
Academic Editor: Kanato Yamagata
Copyright © 2014 Hsin-Yu Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Fatty liver disease is the most common pathological condition in the liver. Here, we generated high-fat diet-(HFD-) induced nonalcoholic fatty liver disease (NAFLD) in mice and tested the effects of docosahexaenoic acid (DHA) and lysine during a four-week regular chow (RC)feeding. Our results showed that 1% lysine and the combination of 1% lysine + 1% DHA reduced body weight. Moreover, serum triglyceride levels were reduced by 1% DHA and 1% lysine, whereas serum alanine transaminase activity was reduced by 1% DHA and 1% DHA + 0.5% lysine. Switching to RC reduced hepatic lipid droplet accumulation, which was further reduced by the addition of DHA or lysine. Furthermore, the mRNA expressions of hepatic proinflammatory cytokines were suppressed by DHA and combinations of DHA + lysine, whereas the mRNA for the lipogenic gene, acetyl-CoA carboxylase 1 (ACC1), was suppressed by DHA. In the gonadal adipose tissues, combinations of DHA and lysine inhibited mRNA expression of lipid metabolism-associated genes, including ACC1, fatty acid synthase, lipoprotein lipase, and perilipin. In conclusion, the present study demonstrated that, in conjunction with RC-induced benefits, supplementation with DHA or lysine further ameliorated the high-fat diet-induced NAFLD and provided an alternative strategy to treat, and potentially prevent, NAFLD.
Obesity, in response to excessive nutrients and energy intake, and inadequate energy expenditure, is recognized as a low-grade and chronic inflammatory state, which leads to the metabolic syndrome, including insulin resistance, type II diabetes, atherosclerosis, hypertension, and fatty liver disease (FLD) [1, 2]. These pathologies are seriously threatening the health of the world populations and knowledge of the underlying mechanisms will provide insights into the future development of preventive and therapeutic strategies.
FLD, also known as hepatosteatosis, is a reversible condition characterized by massive accumulation of triglyceride in the liver cells, due to energy overload and impaired hepatic lipid metabolism . Obesity-associated low-grade and chronic inflammatory response arises from free fatty acid-induced production of proinflammatory cytokines, including TNF-α, IL-1, and IL-6, by metabolic tissues, such as the liver, muscle, and adipose tissue, and by infiltrated immune cells . This impairs insulin sensitivity and metabolic homeostasis, leading to increased hepatic gluconeogenesis and lipogenesis, reduced lipolysis, and reduced muscle glucose uptake and adipose lipolysis [5, 6]. When not properly controlled, FLD may progress toward steatohepatitis or liver cell death, ultimately leading to cirrhosis, liver failure, and hepatocellular carcinoma .
The increasing insulin sensitivity is the major approach to treat nonalcoholic FLD (NAFLD) in humans by means of weight loss, exercise, and use of various drugs [7, 8]. Additionally, nutrients such as docosahexaenoic acid (DHA), a n-3 polyunsaturated fatty acid, have beneficial effects in reducing obesity and the metabolic syndrome  and reducing the occurrence of NAFLD induced by trans-10, cis-12-conjugated linoleic acid [10, 11]. In terms of liver-associated conditions, consumption of n-3 PUFA reduces serum alanine transaminase (ALT) levels, a marker of liver injury due to excessive triglyceride accumulation, in NAFLD patients . In the study of Arai et al. , DHA-enriched fish oil feeding lowers plasma levels of insulin, triglyceride and total cholesterol and liver triglycerides, and fat droplet accumulation compared to the lard/safflower oil-fed group. Also, supplementation of DHA to cultured hepatocytes diminishes hydrogen peroxide-induced oxidative stress and DNA damage, an early event in the initiation and progression of liver injury . As an in vitro NAFLD model, Tai et al.  treated oleic acid-induced SK-HEP-1 cells with DHA and found that the intracellular triglyceride levels are decreased through the reduction of the expression of lipogenic genes, such as sterol regulatory element-binding protein 1c (SREBP-1c), fatty acid synthase (FAS), and acetyl-CoA carboxylase 1(ACC1).
Lysine, an essential amino acid, is important for proper growth and plays a fundamental role in the production of carnitine, a nutrient which shuttles long-chain fatty acids into mitochondria for energy production and assists in lowering the cholesterol levels . In the late 1950s , it was shown that lysine supplementation, with corn as the sole protein source, prevents fatty liver in rats. Upon feeding a lysine/threonine-deficient diet, rats exhibit lowered levels of 20 : 5, 22 : 5, and 22 : 6 fatty acids in hepatic total lipids, suggesting that lysine is associated with the metabolism of polyunsaturated fatty acids (PUFA) . Furthermore, rats fed a diet containing 5% L-lysine exhibit lower serum ALT and aspartate transaminase activities, and this supplementation also effectively protects the rats from the hepatotoxic effects of D-galactosamine .
Given the above-mentioned beneficial effects of DHA and lysine on NAFLD, and the fact that reducing energy intake and increasing physical activities to induce weight loss are generally recommended for patients diagnosed with NAFLD, we propose that supplementation of a regular chow diet (RC; a low-fat diet) with DHA and lysine may have a synergistic effect in improving the fatty liver condition. Both in vivo and in vitro experiments in high-fat diet- (HFD-) fed mice and human hepatic carcinoma SK-HEP-1 cells, respectively, were used to test this hypothesis and suggest an approach to treat NAFLD and elucidate the underlying mechanisms.
2. Materials and Methods
2.1. Animals and Diets
Male C57BL/6 mice (4 weeks of age) were purchased from the National Taiwan University Animal Center and the animal protocol was approved by the Animal Care and Use Committee of National Taiwan University. Mice were fed a high-fat diet (HFD; 35.5% fat; Bioserve F3282, Frenchtown, NJ, USA) for 23 weeks to induce the fatty liver symptom. Body weight was measured every week and blood samples were collected every month. To verify fatty liver induction by histological analysis (see below), two mice were randomly sacrificed from each group after 8, 12, and 16 weeks of feeding. After 23 weeks of HFD feeding, mice were fed regular chow (RC; 4.5% fat; Labdiet 5001, St. Louis, MO, USA) supplemented with different combinations of DHA and lysine, including control (saline), 0.5 and 1% (based on average daily dietary intake) lysine, 1% DHA, 0.5% lysine + 1% DHA, and 1% lysine +1% DHA ( in each group). Mice were treated with each nutrient supplement daily by gavage  for four weeks, during which time the mice were weighed every four days. At the end of the experiment, mice were sacrificed by exposure to carbon dioxide and the liver, gonadal white adipose tissues, and blood samples (from the cheek) were collected. Portions of the livers and white adipose tissues were fixed in formalin for histochemical staining and other portions were snap-frozen in liquid nitrogen and stored at −80°C for future analysis.
2.2. Measurement of Serum Triglyceride and Alanine Transaminase
Blood samples were centrifuged for 15 min at 2000 ×g and the serum samples were stored at −80°C for future analysis. Triglyceride (TG, kit TR 213 from Randox Laboratories, Antrim, UK) and ALT (AL 1268, Randox Laboratories) were colorimetrically measured according to the manufacturer’s instructions. Samples were measured in duplicate and the average was the datum.
2.3. Histological Analysis
Liver tissue was excised from the bottom of the left lobe, fixed in 10% formalin, and embedded in paraffin. Sections of 4 m thickness were sliced and stained with hematoxylin/eosin according to standard procedures.
2.4. Image Analysis
The area of lipid droplets in the liver sections was quantified by the ImageJ software (NIH, Bethesda, MD, USA), which utilizes the color and shape of the images to determine the percentage of lipid droplets in the whole field.
2.5. Cell Culture
Human hepatic carcinoma SK-HEP-1 cells obtained from ATCC were cultured (to ~80% of confluence in a 6 cm dish) in Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Biological industries, Beit Haemek, Israel) at 37°C in an atmosphere of 5% CO2 in air. To induce fat accumulation (as confirmed by oil red O staining), SK-HEP-1 cells were treated with serum-free medium containing 1 mM oleic acid  for 48 hours, followed by 0.1 mM DHA (Cayman Chemical, Ann Arbor, Michigan, USA) and 4 mM lysine (dissolved in deionized water) treatments in serum-free medium containing 1% bovine serum albumin (United States Biological, Swampscott, MA, USA) for 24 hours as previously described .
2.6. Quantitative Reverse Transcription-PCR
To quantify the expression levels of genes associated with hepatic lipid metabolism and inflammation, total RNA was extracted from tissues and cells using TRIzol (Invitrogen, Carlsbad, CA, USA), digested with DNase I (Ambion, Austin, TX 78744, USA) to remove the contamination of genomic DNA, and transcribed to cDNA by High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). Real-time quantitative PCR reactions were performed on CFX96 Real-Time PCR Detection System (Bio-Rad, Richmond, CA, USA) using a DyNAmo Flash SYBR Green Kit (Finnzymes, Espoo, Finland). Running conditions for real-time PCR were initial denaturation at 95°C for 7 min and denaturation at 95°C for 10 s, followed by annealing/extension at 60°C for 30 s for a total of 39 cycles. The primer sequences were listed in Table 1. Threshold cycle (Ct) values were obtained and relative gene expression was calculated using the formula . Values were normalized to -actin levels in the same sample and all measurements were performed in triplicate.
2.7. Statistical Analysis
Statistical significance among different experimental groups was determined by one-way analysis of variance (ANOVA) and Tukey’s test was used to evaluate the differences among the means of different treatments. Results were expressed as mean ± SEM. values ≤ 0.05 were considered statistically significant.
3.1. Induction of NAFLD in Mice by HFD
The HFD induced higher body weight gain (up to ~110% for HFD versus ~55% for RC; see Figure in Supplementary Material available online at http://dx.doi.org/10.1155/2014//310981), massive lipid droplet accumulation in the liver (Figure ), and profound hypertrophy of gonadal adipocytes (Figure ) during the 24-week treatment period.
3.2. RC and Combinations of DHA and Lysine Supplementations Reduced the Body Weight of HFD-Fed Mice
After 23 weeks of HFD feeding and fatty liver induction, body weight was reduced upon RC feeding and DHA and lysine supplementations (Figure 1). As expected, switching to RC, which contains only 4.5% of fat, led to progressive reduction in body weight. However, except at day 24, a somewhat unexpected further reduction, beginning at day four, was observed for the 1% lysine group compared to RC alone control, indicating a beneficial effect of lysine on obesity. The 1% DHA supplementation groups (with or without lysine), at day 24, reduced body weight compared with the RC group, confirming the antiobesity effect of DHA.
3.3. DHA and Lysine Supplemented-RC Feeding Decreased Serum TG and ALT Levels of HFD-Induced Fatty Liver Mice
Because high serum levels of TG and ALT are the hallmarks of NAFLD and liver damage, respectively, we measured their levels and found that, despite the expected suppressive effect of the RC diet on lowering serum TG, mice given 1% DHA, but not lysine, had lower serum TG levels compared to the RC only group (Figure 2(a)). Despite the lack of a synergistic effect, combinations of DHA and lysine also decreased TG levels. ALT, however, was only reduced by 1% DHA and 1% DHA + 0.5% lysine (Figure 2(b)). These results suggest that DHA and lysine exert their beneficial effects by modulating distinct cellular targets and processes.
3.4. DHA and Lysine Supplemented-RC Feeding Ameliorated HFD-Induced NAFLD in Mice
Despite RC-induced body weight loss, histological analysis of the liver revealed that HFD-induced accumulation of lipid droplets remained apparent in the livers of saline control (Figure 3(a)) after switching to RC for 24 days. In sharp contrast, there were only a few smaller droplets in the DHA- and lysine-treated groups. Quantification by image analysis indicated that all groups supplemented with lysine, DHA, or their combinations had reduced hepatic lipid (Figure 3(b)). Histological sections of the gonadal adipose tissues revealed that, consistent with the liver data, combinations of DHA and lysine reduced the size of adipocytes compared to the RC only control without a noticeable difference among the treatment groups (Figure ). Perhaps, adipose lipogenesis contributed to the hepatic lipid content.
3.5. Expression Profiles of Genes Associated with Hepatic Inflammation and Lipid Metabolism
Because low-grade and chronic inflammation and impaired lipid metabolism contribute to NAFLD, we analyzed the effects of DHA and lysine on the expression of hepatic proinflammatory genes, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), monocyte chemotactic protein-1 (MCP1), and interleukin-6 (IL-6) and lipogenic genes, including acetyl-CoA carboxylase1 (ACC1), sterol regulatory element-binding protein 1c (SREBP-1c), and fatty acid synthase (FAS). One percent DHA and 1% DHA + 0.5% lysine reduced IL-1β, TNF-α, MCP-1, and IL-6 mRNA expression (Figure 4(a)). TNF-α and MCP-1 expressions were also decreased by 1% DHA+ 1% lysine treatment compared to the RC only control. In sharp contrast, expression of proinflammatory cytokines was not significantly different among the saline, 0.5% lysine, and 1% lysine groups. For lipogenic genes, only 1% DHA treatment markedly diminished ACC1 mRNA expression (Figure 4(b)). These results suggest that, after weight loss, the beneficial effects of DHA on NAFLD primarily resulted from the suppression of proinflammatory genes, at least at the transcriptional level.
3.6. Expression Profiles of Genes Associated with Lipid Metabolism in Gonadal Adipose Tissues
Because adipose tissue plays a major role in systemic lipid and energy homeostasis and an antiadiposity effect of DHA and lysine in the gonadal adipose tissues was observed (Figure ), the expression of lipid metabolism-associated genes was also analyzed. Supplementation with 1% DHA, 1% DHA + 0.5% lysine, and 1% DHA + 1% lysine, but not lysine alone, markedly reduced gonadal adipose tissue mRNA expression of lipogenic genes, including ACC1, FAS, lipoprotein lipase (LPL) and a lipid droplet-associated protein, and perilipin (Figure 4(c)). These results indicated that DHA supplementation, in the presence or absence of lysine, modulates adiposity and may contribute to the amelioration of hepatosteatosis.
3.7. DHA and Lysine Inhibit FAS and IL-6 Expressions in Human SK-HEP-1 Cells
To verify the in vivo results, a human hepatocellular cell line, SK-HEP-1 cells, was challenged with 1 mM oleic acid  for 48 h to establish a cellular model for fatty liver disease. Then, after a 24 h supplementation of the cell culture medium with 0.1 mM DHA, 4 mM lysine, or 0.1 mM DHA + 4 mM lysine, the expression of the lipogenic gene, FAS was significantly reduced, with no effect on the lipolytic gene, HSL (Figure 5). For inflammatory genes, 0.1 mM DHA, 4 mM lysine, and 0.1 mM DHA + 4 mM lysine consistently reduced the expression of IL-6 and IL-1β, with the latter being of marginal statistical significance (). In summary, these results support the beneficial roles of DHA and lysine in NAFLD through modulating hepatic inflammation and lipid metabolism.
4. Discussion and Conclusion
NAFLD is a worldwide disease, which parallels the frequency of obesity, insulin resistance, metabolic syndrome, and type 2 diabetes . Despite the recent development of therapeutic and preventive strategies [7, 8], treatments with better accessibility, convenience, cost effectiveness, and fewer side effects remain urgently in demand. In the present study, we explored such a strategy by combining the treatments of a low-fat diet, and nutrient supplementations, specifically DHA and lysine, which have separately been shown to ameliorate NAFLD. As expected, switching to RC induced body weight loss and diminishment of hepatic lipid droplet accumulation; these effects were enhanced by DHA and lysine supplementation. Of note was the more profound weight loss by lysine compared to DHA in the early stage of treatment. Moreover, the combined treatments of DHA and lysine essentially restored the hepatosteatotic condition to normal compared to the RC only group. Our current approach suggests an effective approach to treat NAFLD.
To elucidate molecular mechanisms underlying NAFLD and develop therapeutic strategies, an animal model mimicking the natural course and etiological background of this disease is essential. Consistent with previous studies [22–24], our HFD approach induced significant body weight gains (Figure ) with massive lipid droplet accumulation in the liver (Figure ) and profound hypertrophy of adipocytes (Figure ). In rats, 5-week HFD (70% of energy from fat) feeding increases hepatocyte lipid content without changing the body weight . However, we found that 4-week-old male C57BL/6 mice fed a HFD (58.7% of energy from fat) for 23 weeks weighed significantly more than those fed the RC (low-fat chow diet) control diet (Figure ). Yet, similar to the rat data, no significant difference in the serum TG levels (data not shown) was observed between our HFD and RC groups. The species divergence in weight gain plus a longer interval to achieve significant hepatic lipid droplet accumulation in the mice may be attributed to species, composition of diets (59 versus 70% fat), or the duration of HFD feeding.
Since energy overload contributes to obesity and its associated metabolic diseases, including NAFLD, we reduced the energy intake by switching the diet from HFD to RC, mimicking human behavior to eat lighter when diagnosed with fatty liver disease. Switching to low-fat diet indeed reduced the body weight, as well as hepatic lipid droplet accumulation (Figures 1 and 3). Body weight gain and serum ALT activity, a marker of liver damage, are lower in rats fed diets containing 5% lysine compared to the control . After 4 weeks of daily gavage with 0.5% or 1% lysine (based on average of dietary intake), 1% lysine caused additional body weight loss beginning early in the treatment period; this was not observed in other treatment groups except in the 1% lysine + 1% DHA in the latter days of treatment (Figure 1). Perhaps lysine does play a role to increase mitochondrial energy metabolism . Although the slight change of dietary ingredients is not likely to affect feed consumption greatly, we cannot rule out the possibility that a part of weight loss may be due to the difference of food consumption.
Along with the enhanced body weight loss by 1% lysine alone and 1% DHA + 1% lysine (Figure 1), the serum levels of TG were consistently reduced by DHA and its combination with lysine, but not by lysine alone (Figure 2(a)), suggesting that serum TG levels are the target of DHA but not lysine action, which is consistent with a previous human study . DHA, but not lysine, lowered serum ALT activity, except for the 1% lysine + 1% DHA treatment (Figure 2(b)) with a slight but nonsignificant synergistic effect for 1% DHA + 0.5% lysine group. Moreover, it appears that the higher (1%), but not lower, lysine dose neutralizes the beneficial effects of DHA on ALT activities, suggesting that the dose of lysine, when combined with DHA, may be critical in modulating beneficial effects on liver injury.
Weight loss is effective and recommended for the treatment of NAFLD [7, 8]. Indeed, in our current study, after a 4-week RC-induced weight loss, a significant amount, but not all, of the lipid droplets in the livers of HFD-fed mice was eliminated (Figure 3). Eradication of additional lipid droplets by the combined supplementations of DHA and lysine (Figure 3) suggests that DHA and/or lysine may target mechanisms distinct from those of energy homeostasis in hepatic lipid metabolism. While discrete effects of DHA and lysine were observed on body weight and serum ALT activity, DHA, lysine, and their combinations all reduced hepatic lipid (Figure 3(b)).
Supplementation with fish oil or n-3 PUFA decreases serum TG in both mice and humans [9, 10, 12]. Moreover, ultrasonic examination demonstrates an improvement in liver echotexture and improved hemodynamics after n-3 PUFA intake . Mice fed a lard/safflower oil diet have significant hepatic fat droplet accumulation that is inhibited by fish-oil feeding . Because we found that both DHA and lysine decreased hepatic lipid content, but only DHA reduced serum TG and ALT activity, different mechanisms are suggested for the actions of DHA and lysine.
To investigate underlying mechanisms, we analyzed the expression of selected genes associated with inflammation and lipid metabolism in the liver and gonadal adipose tissue. Chronic activation of inflammatory pathways leads to the infiltration of monocytes/macrophages into adipose tissue and liver and the subsequent activation of proinflammatory pathways and cytokine secretion by macrophages . Hepatic TG accumulation may promote the expression of proinflammatory cytokines, which then induce inflammation and lead to neutrophil chemotaxis . Moreover, HFD increases the expression of proinflammatory genes, such as IL-6, TNF-α, MCP-1, and IL-1β, which can be suppressed by n-3 PUFA treatment in mice [27, 29]. Our results also showed that RC supplemented with DHA and lysine, but not saline (RC only), suppressed the expression of hepatic proinflammatory genes (Figure 4(a)), which likely contributed to the enhanced amelioration of NAFLD. In adipose tissue, these genes were numerically, but not statistically, suppressed (data not shown).
Consistent with the reduction in hepatic lipid droplets, 1% DHA supplementation downregulated the expression of hepatic lipogenic genes, such as ACC1 and FAS, but not SREBP-1c (Figure 4(b)). ACC1 and FAS are target genes of SREBP-1c, which is the master transcription factor in hepatic lipogenesis . Because posttranslational modification/processing is necessary to release the bioactive form of SREBP-1c from the ER  and we did not measure the transcriptional activity or the bioactive form, the lack of effect of DHA on SREBP-1c gene expression may not reflect activity of SREBP-1c as a transcription factor. For gonadal adipose tissue, DHA or its combination with lysine, but not lysine only, consistently suppressed the expression of lipogenic genes, such as ACC1, FAS, LPL, and perilipin (Figure 4(c)). This is consistent with the observation of Arai et al.  that fish oil exerts an antiobesity effect through the inhibition of lipid synthesis. In our mice, based on mRNA expression, the effects of DHA to modulate hepatic lipid metabolism were to suppress the inflammatory response and lipid anabolism. Although lysine was expected to decrease the serum ALT levels and the expression of proinflammatory genes, perhaps we did not observe these effects because lysine was administered at only 0.5 and 1%. Because lysine plays an essential role in the production of carnitine, a nutrient that facilitates the conversion of fatty acids into energy , it may contribute to the decreased hepatic lipid accumulation in our mouse study. Lastly, our in vitro model, for the first time, linked lysine to hepatic inflammation by showing that 4 mM lysine reduced IL-6 mRNA expression (Figure 5). The mechanism underlying lysine-modulated inflammation is worthy of further investigation.
In conclusion, we demonstrated that in combination with RC (low-fat diet), DHA treatment decreased serum TG and ALT levels and reduced hepatic lipid droplet accumulation by suppressing hepatic and adipose inflammation and restoring impaired lipid metabolism in mice previously fed HFD. Lysine also effectively reduced lipid accumulation in the liver and enhanced weight loss, but the mechanisms remain to be identified. Our current study thus provides an alternative approach to ameliorate NAFLD by supplementation of caloric-restricted diets with DHA or lysine.
|ACC1:||Acetyl-CoA carboxylase 1|
|ALT:||Serum alanine transaminase|
|ANOVA:||One-way analysis of variance|
|DMEM:||Dulbecco’s Modified Eagle Medium|
|FAS:||Fatty acid synthase|
|FLD:||Fatty liver disease|
|MCP1:||Monocyte chemotactic protein-1|
|PUFA:||Polyunsaturated fatty acid|
|SREBP-1c:||Sterol regulatory element-binding protein 1c|
|TNF-α:||Tumor necrosis factor-alpha.|
Conflict of Interests
The authors declare no conflict of interests.
This project was supported by a Grant (98-2321-B-002-021-MY3) from the National Science Council in Taiwan. C.-C. Chen was supported by the postdoctoral fellowship (101-2811-B-002-020) from the National Science Council in Taiwan.
- M. Hamaguchi, T. Kojima, N. Takeda et al., “The metabolic syndrome as a predictor of nonalcoholic fatty liver disease,” Annals of Internal Medicine, vol. 143, no. 10, pp. 722–I70, 2005.
- J. K. Reddy and M. S. Rao, “Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 290, no. 5, pp. G852–G858, 2006.
- P. Angulo, “Nonalcoholic fatty liver disease,” The New England Journal of Medicine, vol. 346, no. 16, pp. 1221–1231, 2002.
- M. F. Gregor and G. S. Hotamisligil, “Inflammatory mechanisms in obesity,” Annual Review of Immunology, vol. 29, pp. 415–445, 2011.
- S. Lotersztajn, B. Julien, F. Teixeira-Clerc, P. Grenard, and A. Mallat, “Hepatic fibrosis: molecular mechanisms and drug targets,” Annual Review of Pharmacology and Toxicology, vol. 45, pp. 605–628, 2005.
- F. Marra, A. Gastaldelli, G. Svegliati Baroni, G. Tell, and C. Tiribelli, “Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis,” Trends in Molecular Medicine, vol. 14, no. 2, pp. 72–81, 2008.
- C. Thoma, C. P. Day, and M. I. Trenell, “Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review,” Journal of Hepatology, vol. 56, no. 1, pp. 255–266, 2012.
- L. A. Adams and P. Angulo, “Treatment of non-alcoholic fatty liver disease,” Postgraduate Medical Journal, vol. 82, no. 967, pp. 315–322, 2006.
- W. Stillwell, “Docosahexaenoic acid: a most unusual fatty acid,” Chemistry and Physics of Lipids, vol. 153, no. 1, pp. 1–2, 2008.
- C. M. Depner, K. A. Philbrick, and D. B. Jump, “Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr−/− mouse model of western diet-induced nonalcoholic steatohepatitis,” Journal of Nutrition, vol. 143, no. 3, pp. 315–323, 2013.
- D. M. Fedor, Y. Adkins, B. E. Mackey, and D. S. Kelley, “Docosahexaenoic acid prevents trans-10, cis-12-conjugated linoleic acid-induced nonalcoholic fatty liver disease in mice by altering expression of hepatic genes regulating fatty acid synthesis and oxidation,” Metabolic Syndrome and Related Disorders, vol. 10, no. 3, pp. 175–180, 2012.
- M. Capanni, F. Calella, M. R. Biagini et al., “Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study,” Alimentary Pharmacology and Therapeutics, vol. 23, no. 8, pp. 1143–1151, 2006.
- T. Arai, H. J. Kim, H. Chiba, and A. Matsumoto, “Anti-obesity effect of fish oil and fish oil-fenofibrate combination in female KK mice,” Journal of Atherosclerosis and Thrombosis, vol. 16, no. 5, pp. 674–683, 2009.
- A. Gonzalez-Periz, A. Planaguma, K. Gronert et al., “Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA,” The FASEB Journal, vol. 20, no. 14, pp. 2537–2539, 2006.
- C. C. Tai, C. Y. Chen, H. S. Lee et al., “Docosahexaenoic acid enhances hepatic serum amyloid a expression via protein kinase a-dependent mechanism,” The Journal of Biological Chemistry, vol. 284, no. 47, pp. 32239–32247, 2009.
- R. Civitelli, D. T. Villareal, D. Agnusdei, P. Nardi, L. V. Avioli, and C. Gennari, “Dietary L-lysine and calcium metabolism in humans,” Nutrition, vol. 8, no. 6, pp. 400–405, 1992.
- G. P. Vennart, V. P. Perna, and W. B. Stewart, “Fatty liver of portal type: cured by lysine plus tryptophan,” Journal of Nutrition, vol. 64, no. 4, pp. 635–638, 1958.
- R. Viviani, A. M. Sechi, and G. Lenaz, “Fatty acid composition of portal fatty liver in lysine-and threonine-deficient rats,” Journal of Lipid Research, vol. 15, pp. 52–56, 1964.
- B. Wang, M. Ishihara, Y. Egashira, T. Ohta, and H. Sanada, “Effects of various kinds of dietary amino acids on the hepatotoxic action of D-galactosamine in rats,” Bioscience, Biotechnology and Biochemistry, vol. 63, no. 2, pp. 319–322, 1999.
- Q. Deng, H. She, J. H. Cheng et al., “Steatohepatitis induced by intragastric overfeeding in mice,” Hepatology, vol. 42, no. 4, pp. 905–914, 2005.
- T. D. Schmittgen, B. A. Zakrajsek, A. G. Mills, V. Gorn, M. J. Singer, and M. W. Reed, “Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods,” Analytical Biochemistry, vol. 285, no. 2, pp. 194–204, 2000.
- M. D. Weltman, G. C. Farrell, and C. Liddle, “Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation,” Gastroenterologyno, vol. 111, no. 6, pp. 1645–1653, 1996.
- P. Letteron, A. Sutton, A. Mansouri, B. Fromenty, and D. Pessayre, “Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice,” Hepatology, vol. 38, no. 1, pp. 133–140, 2003.
- J. N. Baumgardner, K. Shankar, L. Hennings, T. M. Badger, and M. J. Ronis, “A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 294, no. 1, pp. G27–G38, 2007.
- U. Ahmed, T. G. Redgrave, and P. S. Oates, “Effect of dietary fat to produce non-alcoholic fatty liver in the rat,” Journal of Gastroenterology and Hepatology, vol. 24, no. 8, pp. 1463–1471, 2009.
- K. Hamazaki, M. Itomura, M. Huan et al., “n-3 long-chain FA decrease serum levels of TG and remnant-like particle-cholesterol in humans,” Lipids, vol. 38, no. 4, pp. 353–358, 2003.
- S. Schenk, M. Saberi, and J. M. Olefsky, “Insulin sensitivity: modulation by nutrients and inflammation,” Journal of Clinical Investigation, vol. 118, no. 9, pp. 2992–3002, 2008.
- J. D. Browning and J. D. Horton, “Molecular mediators of hepatic steatosis and liver injury,” Journal of Clinical Investigation, vol. 114, no. 2, pp. 147–152, 2004.
- C. Sun, Z. W. Wei, and Y. Li, “DHA regulates lipogenesis and lipolysis genes in mice adipose and liver,” Molecular Biology Reports, vol. 38, no. 2, pp. 731–737, 2011.
- P. A. Edwards, D. Tabor, H. R. Kast, and A. Venkateswaran, “Regulation of gene expression by SREBP and SCAP,” Biochimica et Biophysica Acta, vol. 1529, no. 1–3, pp. 103–113, 2000.
- D. S. Sachan, T. H. Rhew, and R. A. Ruark, “Ameliorating effects of carnitine and its precursors on alcohol-induced fatty liver,” The American Journal of Clinical Nutrition, vol. 39, no. 5, pp. 738–744, 1984.